reports
Teva to Host Conference Call to Discuss Data from the Completed Phase ...
Teva to Host Conference Call to Discuss Data from the Completed Phase 3 SOLARIS Trial For Olanzapine LAI (TEV-‘749) on September 22, 2025 After Presentations at the Psych Congress Annual meeting TEL AVIV, Israel, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced plans to present data from the completed phase 3 SOLARIS trial at the 2025 Psych Congress Annual Meeting, taking place from September 17 – 21, 2025, in San Diego, California. Teva will also host a conference call for analysts and investors on Monday, September 2...
- Si Yong Ng
- Felix Fischer
- Haidje Rustau
- Jayanth Kandalam
- Peter Low
- Si Yong Ng
- Tanvi Arora
Lucror Analytics - Morning Views Europe
In today's Morning Views publication we comment on developments of the following high yield issuers: Mahle, Guala Closures, Playtech, Grupo Antolin, NewDay, Kiloutou, David Lloyd Leisure, Omnia Technologies, Cirsa, evoke, Derichebourg, Seche Environnement, Samvardhana Motherson, Teva
Teva’s Emrusolmin Granted U.S. FDA Fast Track Designation for Treatmen...
Teva’s Emrusolmin Granted U.S. FDA Fast Track Designation for Treatment of Multiple System Atrophy Teva received Fast Track designation from the U.S. Food and Drug Administration for emrusolmin (TEV-56286), an investigational treatment for Multiple System Atrophy (MSA) in Phase 2 development.New therapeutic options for people living with MSA, a rare and devastating neurodegenerative disorder, are urgently needed as there are no treatments available that impact disease progression.Emrusolmin is a small molecule that targets the alpha synuclein protein, which is believed to be pivotally invol...
Teva to Present at Morgan Stanley Global Healthcare Conference and Ban...
Teva to Present at Morgan Stanley Global Healthcare Conference and Bank of America Global Healthcare Conference in September TEL AVIV, Israel, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at two upcoming investor conferences in September as follows: Morgan Stanley 23rd Annual Global Healthcare ConferenceTuesday, September 9, 2025, at 8:30 A.M. ET BofA Global Healthcare Conference 2025 (London)Wednesday, September 24, 2025, at 9:00 A.M. ...
Teva Announces FDA Approval and Launch of Generic Saxenda® (liraglutid...
Teva Announces FDA Approval and Launch of Generic Saxenda® (liraglutide injection) – First Generic GLP-1 Indicated for Weight Loss Generic Saxenda® is the first-ever generic GLP-1 indicated for weight loss, addressing increased demand for this category of therapies in the U.S. market.This approval and launch add to Teva’s continued commitment to its complex generic medicine portfolio as part of its Pivot to Growth Strategy.Liraglutide injection is indicated for adults with obesity or overweight (excess weight) who also have weight related medical problems, and pediatric patients (12-17 year...
FDA Approves Expanded Indication for AJOVY® (fremanezumab-vfrm), The F...
FDA Approves Expanded Indication for AJOVY® (fremanezumab-vfrm), The First Anti-CGRP Preventive Treatment for Pediatric Episodic Migraine FDA approves single-dose AJOVY® (fremanezumab-vfrm) injection for the preventive treatment of episodic migraine in children and adolescents aged 6-17 who weigh 45 kilograms or more, offering a long-awaited monthly treatment option with in-office or at-home administration1AJOVY expands access across age groups as the first and only calcitonin gene-related peptide (CGRP) antagonist approved for pediatric episodic migraine prevention and migraine prevention ...
- Si Yong Ng
Teva - Earnings Flash - Q2 FY 2025 Results - Lucror Analytics
Teva has reported good Q2/25 numbers, with adjusted EBITDA rising y-o-y. While reported sales were broadly flat, they would have increased if adjusting for the disposal of the Japan business venture (BV). Cash generation improved. Reported net leverage was broadly flat q-o-q, while liquidity remained adequate. We anticipate decent H2/25 results, with continued top-line-supported growth in Austedo, Ajovy and Uzedy to offset headwinds from the Japan BV disposal. Profitability should benefit fr...
- Josseline Jenssen
- Si Yong Ng
- Felix Fischer
- Haidje Rustau
- Jayanth Kandalam
- Peter Low
- Si Yong Ng
- Tanvi Arora
- Trung Nguyen
Lucror Analytics - Morning Views Europe
In today's Morning Views publication we comment on developments of the following high yield issuers: Trivium, Applus, Altice France (SFR), Casino Guichard-Perrachon, International Personal Finance, TeamSystem, Aston Martin, Virgin Media O2, Liberty Global, TalkTalk, Recordati, Tata Motors, Nexans, Italmatch Chemicals, Itelyum Group, Teva
TEVA.N TEVA PHARMACEUTICAL INDUSTRIES LIMITED SPONSORED ADR
LBTYA LIBERTY GLOBAL PLC CLASS A
NEX NEXANS SA
IPF INTERNATIONAL PERSONAL FINANCE PLC
REC RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.P.A.
TALK TALKTALK TELECOM GROUP PLC
TATAMOTORS TATA MOTORS LIMITED
AML ASTON MARTIN LAGONDA GLOBAL HOLDINGS PLC
Teva's Innovative Portfolio Fuels 10th Consecutive Quarter of Growth i...
Teva's Innovative Portfolio Fuels 10th Consecutive Quarter of Growth in Q2 2025; Increases 2025 Revenue Outlook for Key Innovative Products and EPS, and Reaffirms All Other Components On track for 30% operating profit margin by 2027 in line with our Pivot to Growth Strategy.Q2 2025 shows 10th consecutive quarter of year-over-year (YoY) revenue growth; Revenues of $4.2 billion, +1% in local currencyterms (“LC“)excluding Japan BV revenues; United States segment +2%; Europe segment +3% in LC; International Markets segment -4% inLCand excluding Japan BV revenues. Innovative portfolio continu...
- Felix Fischer
- Si Yong Ng
- Felix Fischer
- Haidje Rustau
- Jayanth Kandalam
- Peter Low
- Si Yong Ng
Lucror Analytics - Morning Views Europe
In today's Morning Views publication we comment on developments of the following high yield issuers: Ardagh, Teva, TeamSystem, Digi Communications, Selecta, Rexel, Gestamp, Forvia (formerly Faurecia), Nexans, International Personal Finance, Ineos, AMS Osram, OPmobility, Intrum
Teva Releases Q2 2025 Aide Memoire
Teva Releases Q2 2025 Aide Memoire TEL AVIV, Israel, June 26, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q2 2025 Aide Memoire is available on the “Investors” page on its website. Teva has prepared this document to assist in the financial modeling of its quarterly results. The document is based on Teva’s prior results, management’s previous commentary about Teva’s business outlook and data from select independent sources. About Teva Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a different kind of ...
Teva to Host Conference Call to Discuss Second Quarter 2025 Financial ...
Teva to Host Conference Call to Discuss Second Quarter 2025 Financial Results at 8 a.m. ET on July 30, 2025 TEL AVIV, Israel, June 25, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its second quarter 2025 financial results on Wednesday, July 30, 2025, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET. In order to participate, please register in advance to obtain a local or toll-free phone number and your personal pin. A l...
Abschließende Daten aus der realen PEARL-Studie von Teva untermauern d...
Abschließende Daten aus der realen PEARL-Studie von Teva untermauern die langfristige Wirksamkeit von AJOVY® (fremanezumab) für die Prävention chronischer und episodischer Migräne Die abschließende Analyse der realen PEARL-Studie für die Migräneprävention wurde auf dem 11. Kongress der European Academy of Neurology (EAN 2025) in Helsinki präsentiert1,2Fremanezumab demonstrierte eine langfristige Wirksamkeit und ein günstiges Sicherheits- und Verträglichkeitsprofil über den zweijährigen Untersuchungszeitraum1,2Über die gesamte Studie wurde eine hohe Injektionsadhärenz eingehalten (~90 %), gl...
Les données définitives de l’étude PEARL menée par Teva en conditions ...
Les données définitives de l’étude PEARL menée par Teva en conditions réelles confirment l’efficacité à long terme d’AJOVY® (frémanézumab) pour la prévention de la migraine chronique et épisodique L’analyse finale de l’étude PEARL ciblée sur la prévention de la migraine en conditions réelles a été présentée au 11ᵉ congrès de l’Académie européenne de neurologie (le congrès EAN 2025) qui s’est tenu à Helsinki1,2Le frémanézumab a montré une efficacité durable ainsi qu’un profil d’innocuité et de tolérabilité favorable au cours de la période d’étude de deux ans1,2L’observance des injections est...
Final Data from Teva’s PEARL Real-World Study Reinforce the Long-term ...
Final Data from Teva’s PEARL Real-World Study Reinforce the Long-term Effectiveness of AJOVY® (fremanezumab) for the Prevention of Chronic and Episodic Migraine Final analysis of PEARL real world migraine prevention study presented at 11th Congress of the European Academy of Neurology (EAN 2025) Congress in Helsinki1,2Fremanezumab demonstrated sustained effectiveness and a favourable safety and tolerability profile over the two-year study period1,2Injection adherence remained high throughout the study (~90%), while over 75% of patients completed the study duration1 TEL AVIV, Israel, ...
Teva Pharmaceutical Industries Ltd: 1 director
A director at Teva Pharmaceutical Industries Ltd sold 55,775 shares at 17.077USD and the significance rating of the trade was 71/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the las...
Teva and Fosun Pharma Enter into a Strategic Partnership to Develop No...
Teva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology Teva-engineered TEV-56278 is an anti-PD1-IL2 ATTENUKINE™ therapy in Phase 1 for the treatment of various forms of cancer, including melanomaFosun Pharma-Teva collaboration agreement established with goal of accelerating clinical data generation for TEV-56278Partnership leverages strategic relationships to enable research and development of innovative treatments to advance Teva's Pivot to Growth strategy TEL AVIV, Israel and SHANGHAI, June 16, 2025 (GLOBE NEW...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.